spk-8016
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 30, 2019 (NCT03734588)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenoviridae · Phase 1/Phase 2
- Blood Coagulation Disorders · Phase 1/Phase 2
- Blood Coagulation Disorders, Inherited · Phase 1/Phase 2
- Coagulation Protein Disorders · Phase 1/Phase 2
- Drugs, Investigational · Phase 1/Phase 2
- Factor VIII · Phase 1/Phase 2
- Genetic Diseases, Inborn · Phase 1/Phase 2
- Genetic Diseases, X-Linked · Phase 1/Phase 2
- Genetic Therapy · Phase 1/Phase 2
- Hematologic Diseases · Phase 1/Phase 2
- Hemorrhagic Disorders · Phase 1/Phase 2
Mechanism of action
- Coagulation factor VIIISupplementation
F8 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03734588 | Phase 1/Phase 2 (Phase 2) | Jan 30, 2019 | Spark Therapeutics, University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spark Therapeutics | For profit | 1 | 1 | 1 | 2019 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1